天宇股份(300702.SZ)子公司磷酸西格列汀原料药通过CDE评审

智通财经09-04 18:52

智通财经APP讯，天宇股份(300702.SZ)发布公告，公司全资子公司浙江京圣药业有限公司磷酸西格列汀原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。磷酸西格列汀是一种降糖药，能够帮助控制血糖水平，主要用于治疗2型糖尿病。磷酸西格列汀原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP符合性检查结果为“符合要求”的公示后，方可在国内上市销售。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2664485336?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-04 18:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664485336","market":"us","top_or_hot":-1,"title":"天宇股份(300702.SZ)子公司磷酸西格列汀原料药通过CDE评审","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/300702\">天宇股份</a>(300702.SZ)发布公告，公司全资子公司浙江京圣药业有限公司磷酸西格列汀原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。磷酸西格列汀是一种降糖药，能够帮助控制血糖水平，主要用于治疗2型糖尿病。磷酸西格列汀原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP符合性检查结果为“符合要求”的公示后，方可在国内上市销售。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天宇股份(300702.SZ)子公司磷酸西格列汀原料药通过CDE评审</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天宇股份(300702.SZ)子公司磷酸西格列汀原料药通过CDE评审\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/300702\">天宇股份</a>(300702.SZ)发布公告，公司全资子公司浙江京圣药业有限公司磷酸西格列汀原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。磷酸西格列汀是一种降糖药，能够帮助控制血糖水平，主要用于治疗2型糖尿病。磷酸西格列汀原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP符合性检查结果为“符合要求”的公示后，方可在国内上市销售。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1492208.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGDM","symbol_name":"Sprott Gold Miners ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1492208.html","article_id":"2664485336","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664485336","pubTimestamp":1788519175,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，天宇股份(300702.SZ)发布公告，公司全资子公司浙江京圣药业有限公司磷酸西格列汀原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。磷酸西格列汀是一种降糖药，能够帮助控制血糖水平，主要用于治疗2型糖尿病。磷酸西格列汀原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP符合性检查结果为“符合要求”的公示后，方可在国内上市销售。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300702":"天宇股份","SGDM":"Sprott Gold Miners ETF","LU1223083913.SGD":"Schroder ISF Global Gold A Acc SGD-H","GDXJ":"小型黄金矿业ETF(Market Vectors)","LU1223082519.USD":"SCHRODER ISF GLOBAL GOLD \"A\" (USD) INC AV","LU1223082196.USD":"施罗德环球黄金A Acc","BK0239":"医药制造","SIL":"Silver Miners Etf","XME":"金属与采矿指数ETF-SPDR","CDE":"科尔黛伦矿业","BK4017":"黄金"},"translate_title":"Tianyu Co., Ltd. (300702.SZ) subsidiary Sitagliptin phosphate API passes CDE review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300702":1.5,"SIL":0.6,"GDXJ":0.6,"SGDM":0.6,"XME":0.6,"CDE":1.5},"content_text":"智通财经APP讯，天宇股份(300702.SZ)发布公告，公司全资子公司浙江京圣药业有限公司磷酸西格列汀原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。磷酸西格列汀是一种降糖药，能够帮助控制血糖水平，主要用于治疗2型糖尿病。磷酸西格列汀原料药现已通过CDE审评，尚须取得浙江省药品监督管理局GMP符合性检查结果为“符合要求”的公示后，方可在国内上市销售。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2664485336","isCrawlerRequest":true}